Literature DB >> 12761605

Paracetamol and metabolite pharmacokinetics in infants.

Caroline D van der Marel1, Brian J Anderson, Richard A van Lingen, Nicholas H G Holford, Marien A L Pluim, Frank G A Jansman, John N van den Anker, Dick Tibboel.   

Abstract

BACKGROUND: Data concerning metabolism of paracetamol in infants are scant. Previous studies have examined urinary metabolite recovery rates after a single dose of paracetamol in either neonates (<6 weeks) or children (3-9 years). There are no studies investigating infants.
METHODS: Infants ( n=47) undergoing major craniofacial surgery were given paracetamol 19-45 mg/kg 6-, 8-, or 12-hourly as either elixir or suppository formulation for postoperative analgesia, after a loading dose of 33-59 mg/kg rectally during the operation. Serum was assayed for paracetamol concentration in 40 of these infants at 5, 8, 11, 14, 17 and 20 h postoperatively. Urine samples were collected every 3 h for 24 h in 15 of these infants. The clearances of paracetamol to glucuronide and sulphate metabolites as well as the urinary clearance of unmetabolised paracetamol were estimated using non-linear, mixed-effects models.
RESULTS: Mean (+/-SD) age and weight of the patients were 11.8+/-2.5 months and 9.1+/-1.9 kg. Clearances of paracetamol to paracetamol-glucuronide (%CV) and to paracetamol-sulphate were 6.6 (11.5) l/h and 7.5 (11.5) l/h respectively, standardised to a 70-kg person using allometric "1/4 power" models. Glucuronide formation clearance, but not sulphate formation, was related to age and increased with age from a predicted value in a neonate of 2.73 l/h/70 kg to a mature value of 6.6 l/h/70 kg with a maturation half-life of 8.09 months. Urine clearance of paracetamol-glucuronide, paracetamol-sulphate and unchanged paracetamol (%CV) were, respectively, 2.65, 3.03 and 0.55 (28) l/h/70 kg. The urine clearance of unchanged paracetamol and metabolites was related to urine volume flow rate. Clearance attributable to pathways other than these measured in urine was not identifiable. The glucuronide/sulphate formation clearance ratio was 0.69 at 12 months of age. Sulphate metabolism contributed 50% towards paracetamol clearance.
CONCLUSION: Glucuronide formation clearance increases with age in the infant age range but sulphate formation does not. Renal clearance of paracetamol and its metabolites increases with urine flow rate. This and other studies show that paracetamol metabolism to glucuronide appears to be similar in infants and children, but in adults is increased in comparison with children. Oxidative pathways were undetectable in this infant study and may explain, in part, the reduced incidence of hepatotoxicity in infants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761605     DOI: 10.1007/s00228-003-0608-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  37 in total

Review 1.  Drug use in the neonate: interrelationships of pharmacokinetics, toxicity, and biochemical maturity.

Authors:  A Warner
Journal:  Clin Chem       Date:  1986-05       Impact factor: 8.327

2.  Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation.

Authors:  P T Manyike; E D Kharasch; T F Kalhorn; J T Slattery
Journal:  Clin Pharmacol Ther       Date:  2000-03       Impact factor: 6.875

3.  Therapeutic doses of codeine have no effect on acetaminophen clearance or metabolism.

Authors:  J Sonne; H E Poulsen; S Loft; M Døssing; A Vollmer-Larsen; K Simonsen; H Thyssen; K Lundstrøm
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Comparison of paracetamol metabolism in young adult and elderly males.

Authors:  J O Miners; R Penhall; R A Robson; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Effects of oral contraceptive steroids on acetaminophen metabolism and elimination.

Authors:  M C Mitchell; T Hanew; C G Meredith; S Schenker
Journal:  Clin Pharmacol Ther       Date:  1983-07       Impact factor: 6.875

6.  Circadian rhythm of serum sulfate levels in man and acetaminophen pharmacokinetics.

Authors:  D A Hoffman; S M Wallace; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates.

Authors:  R A van Lingen; J T Deinum; J M Quak; A J Kuizenga; J G van Dam; K J Anand; D Tibboel; A Okken
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

8.  Effects of posture and sleep on the pharmacokinetics of paracetamol (acetaminophen) and its metabolites.

Authors:  R H Rumble; M S Roberts; M J Denton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

9.  The association of age and frailty with paracetamol conjugation in man.

Authors:  H A Wynne; L H Cope; B Herd; M D Rawlins; O F James; K W Woodhouse
Journal:  Age Ageing       Date:  1990-11       Impact factor: 10.668

Review 10.  Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view.

Authors:  K Bergman; L Müller; S W Teigen
Journal:  Mutat Res       Date:  1996-02-01       Impact factor: 2.433

View more
  23 in total

1.  No urine, no urinary clearance.

Authors:  Brian J Anderson; Nicholas H G Holford
Journal:  Eur J Clin Pharmacol       Date:  2004-05-18       Impact factor: 2.953

2.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.

Authors:  Gudrun Würthwein; Susanne Koling; Alexander Reich; Georg Hempel; Petra Schulze-Westhoff; Paulo V Pinheiro; Joachim Boos
Journal:  Eur J Clin Pharmacol       Date:  2005-01-21       Impact factor: 2.953

5.  Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever.

Authors:  Athena F Zuppa; Gregory B Hammer; Jeffrey S Barrett; Brian F Kenney; Nastya Kassir; Samer Mouksassi; Mike A Royal
Journal:  J Pediatr Pharmacol Ther       Date:  2011-10

Review 6.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

7.  Prenatal exposure to acetaminophen and respiratory symptoms in the first year of life.

Authors:  Victoria Persky; Julie Piorkowski; Eva Hernandez; Noel Chavez; Cynthia Wagner-Cassanova; Carmen Vergara; Darlene Pelzel; Rachel Enriquez; Silvia Gutierrez; Adela Busso
Journal:  Ann Allergy Asthma Immunol       Date:  2008-09       Impact factor: 6.347

8.  Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates.

Authors:  Karel Allegaert; Brian J Anderson; Gunnar Naulaers; Jan de Hoon; Rene Verbesselt; Anne Debeer; Hugo Devlieger; Dick Tibboel
Journal:  Eur J Clin Pharmacol       Date:  2004-04-08       Impact factor: 2.953

9.  Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model.

Authors:  Sarah F Cook; Chris Stockmann; Samira Samiee-Zafarghandy; Amber D King; Nina Deutsch; Elaine F Williams; Diana G Wilkins; Catherine M T Sherwin; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

10.  A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.

Authors:  Gary Ginsberg; Suryanarayana V Vulimiri; Yu-Sheng Lin; Jayaram Kancherla; Brenda Foos; Babasaheb Sonawane
Journal:  J Toxicol Environ Health A       Date:  2017-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.